Andreas Kovar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Andreas Kovar has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Abdullah Hamadeh
School of Pharmacy University of Waterloo Kitchener Ontario Canada
1 shared publication Alexander Staab
Clinical Pharmacology Boehringer Ingelheim Pharma GmbH & co. KG Ingelheim am Rhein Germany
1 shared publication- Amel Lahmar
Sanofi Bridgewater New Jersey USA
1 shared publication - André Dallmann
Bayer HealthCare SAS, on Behalf of: Model‐Informed Drug Development, Research & Development, Pharmaceuticals, Bayer AG Leverkusen Germany
1 shared publication - Annika R. P. Schneider
Model‐Informed Drug Development, Research & Development, Pharmaceuticals Bayer AG Leverkusen Germany
1 shared publication - Bernd Meibohm
Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center
1 shared publication
Latest Publications
- Open Access
- 3 April 2025
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 14 (5) , 822-827
Harnessing Open‐Source Solutions: Insights From the First Open Systems Pharmacology ( OSP ) Community Conference
In 2017, the free and open‐source software Open Systems Pharmacology (OSP) was launched. Since then, OSP has evolved from a small community into a diverse network of stakeholders committed to advancing open‐source solutions for model‐informed drug development (MIDD). In this context, the first OSP Community Conference was hosted by Novartis in Basel, Switzerland, on October 7–8, 2024, which gathered over 100 attendees from more than 40 institutions. This perspective synthesizes key insights from the conference.
- 3 April 2025
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 14 (5) , 822-827
Open AccessHarnessing Open‐Source Solutions: Insights From the First Open Systems Pharmacology ( OSP ) Community Conference
In 2017, the free and open‐source software Open Systems Pharmacology (OSP) was launched. Since then, OSP has evolved from a small community into a diverse network of stakeholders committed to advancing open‐source solutions for model‐informed drug development (MIDD). In this context, the first OSP Community Conference was hosted by Novartis in Basel, Switzerland, on October 7–8, 2024, which gathered over 100 attendees from more than 40 institutions. This perspective synthesizes key insights from the conference.
- Open Access
- 30 March 2025
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 118 (1) , 164-176
First‐in‐Human Single and Multiple Ascending Dose Studies of Balinatunfib, a Small Molecule Inhibitor of TNFR1 Signaling in Healthy Participants
Oral small molecule inhibitors of tumor necrosis factor alpha (TNFα) are emerging as attractive therapeutic agents for the treatment of various autoimmune diseases. Balinatunfib (SAR441566), a novel oral inhibitor of tumor necrosis factor receptor 1 (TNFR1) signaling, changes the configuration of the soluble TNFα (sTNFα) trimer and prevents its heterotrimerization with TNFR1 but not TNFR2, thereby blocking TNFR1 signaling. Herein, we report the results from a first‐in‐human (FIH) study that evaluated the safety, pharmacokinetics (PK), and pharmacodynamics (PD) following single ascending doses (SAD) and multiple ascending doses (MAD) of balinatunfib in healthy male participants. Single (5–600 mg) and multiple (100–600 mg total daily dose for up to 14 days) oral doses of balinatunfib were well‐tolerated in all participants. Consistent PK data were obtained across the studies, with a median tmax of 2.5–5 hours, a mean terminal half‐life of 22–30 hours, and a time to steady state of 5–6 days. A supra‐proportional exposure increase was observed in both SAD and MAD studies, which was less pronounced at doses ≥ 180 mg. Food had no relevant effects on the PK characteristics of balinatunfib. As the main PD read‐out, complete TNFα occupancy was shown at all tested time points after the treatment started. Balinatunfib, as the first clinically tested oral TNFR1 signal inhibitor, demonstrated a good safety profile along with favorable PK/PD characteristics that allowed both once and twice daily dosing, confirming a successful preclinical‐to‐clinical translation and guiding dose selection for further clinical efficacy studies.
- 30 March 2025
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 118 (1) , 164-176
Open AccessFirst‐in‐Human Single and Multiple Ascending Dose Studies of Balinatunfib, a Small Molecule Inhibitor of TNFR1 Signaling in Healthy Participants
Oral small molecule inhibitors of tumor necrosis factor alpha (TNFα) are emerging as attractive therapeutic agents for the treatment of various autoimmune diseases. Balinatunfib (SAR441566), a novel oral inhibitor of tumor necrosis factor receptor 1 (TNFR1) signaling, changes the configuration of the soluble TNFα (sTNFα) trimer and prevents its heterotrimerization with TNFR1 but not TNFR2, thereby blocking TNFR1 signaling. Herein, we report the results from a first‐in‐human (FIH) study that evaluated the safety, pharmacokinetics (PK), and pharmacodynamics (PD) following single ascending doses (SAD) and multiple ascending doses (MAD) of balinatunfib in healthy male participants. Single (5–600 mg) and multiple (100–600 mg total daily dose for up to 14 days) oral doses of balinatunfib were well‐tolerated in all participants. Consistent PK data were obtained across the studies, with a median tmax of 2.5–5 hours, a mean terminal half‐life of 22–30 hours, and a time to steady state of 5–6 days. A supra‐proportional exposure increase was observed in both SAD and MAD studies, which was less pronounced at doses ≥ 180 mg. Food had no relevant effects on the PK characteristics of balinatunfib. As the main PD read‐out, complete TNFα occupancy was shown at all tested time points after the treatment started. Balinatunfib, as the first clinically tested oral TNFR1 signal inhibitor, demonstrated a good safety profile along with favorable PK/PD characteristics that allowed both once and twice daily dosing, confirming a successful preclinical‐to‐clinical translation and guiding dose selection for further clinical efficacy studies.
- Open Access
- 18 October 2011
- Published by Springer Nature in The AAPS Journal
- Vol. 13 (4) , 650-661
Comparative Performance of Cell Life Span and Cell Transit Models for Describing Erythropoietic Drug Effects
Prolonged time delay in response to drug action is a common feature of hematological responses to pharmacotherapy such as erythropoiesis. The objective of this study was to compare the performance of two competing modeling approaches for delayed drug effects, mechanistic cell life span models, and semi-mechanistic cell transit models. The comparison was performed with an experimental dataset from multiple dose administrations of an erythropoietin mimetic to Cynomolgus monkeys. Comparative performance measures include visual predictive checks, goodness-of-fit plots, model estimation time, estimation status, and estimation error. The analysis revealed that both models resulted in a similarly good description of the erythropoietic drug effect, with precision and bias of the model-based predictions of red blood cell counts of less than 11%. The cell transit model needed slightly longer time to converge compared to the cell life span model. The system and drug effect parameters were similar in both models indicating that the models can be interchangeably used to describe the current data. Thus, model selection would be dependent on the purpose of the modeling exercise, the available data, and the time allocated for model development.
- 18 October 2011
- Published by Springer Nature in The AAPS Journal
- Vol. 13 (4) , 650-661
Open AccessComparative Performance of Cell Life Span and Cell Transit Models for Describing Erythropoietic Drug Effects
Prolonged time delay in response to drug action is a common feature of hematological responses to pharmacotherapy such as erythropoiesis. The objective of this study was to compare the performance of two competing modeling approaches for delayed drug effects, mechanistic cell life span models, and semi-mechanistic cell transit models. The comparison was performed with an experimental dataset from multiple dose administrations of an erythropoietin mimetic to Cynomolgus monkeys. Comparative performance measures include visual predictive checks, goodness-of-fit plots, model estimation time, estimation status, and estimation error. The analysis revealed that both models resulted in a similarly good description of the erythropoietic drug effect, with precision and bias of the model-based predictions of red blood cell counts of less than 11%. The cell transit model needed slightly longer time to converge compared to the cell life span model. The system and drug effect parameters were similar in both models indicating that the models can be interchangeably used to describe the current data. Thus, model selection would be dependent on the purpose of the modeling exercise, the available data, and the time allocated for model development.